These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11762819)

  • 1. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
    Seymour JF; Grigg AP; Szer J; Fox RM
    Ann Oncol; 2001 Oct; 12(10):1455-60. PubMed ID: 11762819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
    Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
    Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
    McLaughlin P; Hagemeister FB; Romaguera JE; Sarris AH; Pate O; Younes A; Swan F; Keating M; Cabanillas F
    J Clin Oncol; 1996 Apr; 14(4):1262-8. PubMed ID: 8648382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
    Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
    J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
    Seymour JF; Grigg AP; Szer J; Fox RM
    Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial.
    Emmanouilides C; Rosen P; Rasti S; Territo M; Kunkel L
    Hematol Oncol; 1998 Sep; 16(3):107-16. PubMed ID: 10235069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
    Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
    Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
    Velasquez WS; Lew D; Grogan TM; Spiridonidis CH; Balcerzak SP; Dakhil SR; Miller TP; Lanier KS; Chapman RA; Fisher RI;
    J Clin Oncol; 2003 May; 21(10):1996-2003. PubMed ID: 12743154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
    Dimopoulos MA; Fountzilas G; Papageorgiou E; Kiamouris C; Mantzios G; Anagnostopoulos A; Nicolaides C; Economopoulos T;
    Leuk Lymphoma; 2002 Jan; 43(1):111-4. PubMed ID: 11908713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
    Rao R; Shammo JM; Enschede SH; Porter C; Adler SS; Venugopal P; Gregory SA
    Clin Lymphoma; 2005 Jun; 6(1):26-30. PubMed ID: 15989703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
    McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
    Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
    Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
    Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
    Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M
    Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
    Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F
    Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
    Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
    Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A; Colbert A; Lechowicz MJ; Flowers CR
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):514-8. PubMed ID: 26297176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.